$APVO News

Aptevo Provides 2Q26 Business Update and Reports Second Quarter Financial Results

Aptevo Therapeutics Q2 EPS $(5.31) Beats $(6.16) Estimate

Aptevo Therapeutics Announces Closing of Existing Warrants Exercise and PIPE for $4.5 Million Gross Proceeds

Aptevo Therapeutics Closes Warrant Inducement Transaction, Issuing New Warrants For 1.27M Shares At $4.03 Per Share; Sells 861,708 Shares In $4.03 PIPE

Aptevo Therapeutics Announces Exercise of Existing Warrants and PIPE for $4.5 Million Gross Proceeds

Reported Earlier: Aptevo Therapeutics Announces A New Solid Strategy Designed To Fight Cancer On Multiple Fronts; Files A Patent Application Covering A Proprietary Nectin-4 X PD-L1 Dual-Targeting Backbone Designed To Strengthen Aptevo's Oncology Pipeline

Aptevo Strengthens Solid Tumor Strategy with Patent Filing for Nectin-4 x PD-L1 Dual Targeting Backbone

Aptevo Therapeutics Has Received A Notice Of Allowance For A U.S. Patent Titled "4-1BB AND OX40 BINDING PROTEINS AND RELATED COMPOSITIONS AND METHODS, ANTIBODIES AGAINST 4-1BB, ANTIBODIES AGAINST OX40 (FOR THE TREATMENT OF CANCER)".

Aptevo Secures $1.5 Million Non-Dilutive Research Grant From the Andy Hill Care Fund to Advance APVO451, a Nectin-4-Targeted Trispecific Immunotherapy for Solid Tumors

APVO: Initiating Coverage of Aptevo Therapeutics Inc.; Unlocking the Next Generation of Multispecific Immune Engagement

Aptevo Therapeutics Appoints Mary J. Janatpour, Ph.D., as Senior Vice President & Chief Scientific Officer

Aptevo Therapeutics Has Received A Notice Of Allowance For A U.S. Patent Titled "PROSTATE-SPECIFIC MEMBRANE ANTIGEN BINDING PROTEINS AND RELATED COMPOSITIONS AND METHODS (FOR THE TREATMENT OF PROSTATE CANCER)".

Aptevo and Niowave Launch Strategic Collaboration for Radiopharmaceutical Therapeutic Development, Includes Strategic Equity Investment by Niowave at Closing

Aptevo Therapeutics Partners With Niowave To Develop Up To Three Radiopharmaceutical Oncology Programs

All You Need to Know About Aptevo Therapeutics (APVO) Rating Upgrade to Buy

Aptevo Therapeutics Provides a 1Q26 Business Update; RAINIER on Track for 2026 Completion and Phase 2 Dose Selection

Aptevo Reports 87% Clinical Benefit and 81% Remission in 31 Evaluable Frontline AML Patients Through Cohort 5, Substantially Outperforming Benchmark; RAINIER on Track for 2026 Completion and Phase 2 Dose Selection

Aptevo Therapeutic Announces 87% clinical benefit rate And 81% Remission Rate In Its RAINIER Frontline Acute Myeloid Leukemia Trial, RAINIER Remains On Schedule For 2026 Completion And Phase 2 Dose Selection

Aptevo Therapeutics (APVO) Upgraded to Buy: Here's Why

Aptevo Therapeutics Q4 EPS $(6.23) Beats $(8.10) Estimate